Elon's Vision
  • Contacts
  • Privacy Policy
  • Terms & Conditions
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
No Result
View All Result
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
No Result
View All Result
Elon's Vision
No Result
View All Result
Home Editor's Pick

Minnesota Repeals Its Drug Paraphernalia Laws

by
May 24, 2023
in Editor's Pick
0
0
SHARES
6
VIEWS
Share on FacebookShare on Twitter

Jeffrey A. Singer

On May 19, Minnesota Governor Tim Walz signed into law a bill legalizing all drug paraphernalia, including testing equipment and syringes, and decriminalizing drug residue. As Sophia Heimowitz and I explained in our Cato policy analysis last year, drug paraphernalia laws stand in the way of harm reduction organizations that seek to help people who use drugs avoid drug overdoses and the spread of infectious diseases.

In the late 1970s, the Drug Enforcement Administration began successfully encouraging states to enact drug paraphernalia laws and even developed and provided model legislation. Our study found that Alaska is the only state that never enacted drug paraphernalia laws. Our policy analysis called on all other states to emulate Alaska by repealing their drug paraphernalia laws.

Last June, I moderated a Cato online policy forum in which the Executive Director of Alaska’s oldest harm reduction organization compared notes with the Executive Director of Arizona’s oldest and largest harm reduction organization.

Arizona amended its paraphernalia laws in 2021 to permit syringe services programs to operate and to allow distributing and using fentanyl test strips. Still, it left most of the drug paraphernalia law intact. Minnesota, however, has gone even further by becoming the first state to repeal its drug paraphernalia laws. The law takes effect on August 1.

Hopefully, the remaining states will follow Minnesota’s lead.

Previous Post

The Fed Is Overindebted, Isn’t It?

Next Post

Passport Waiting Time Secures We Jump Any Line to Enhance Customers’ Travel Experience

Next Post

Passport Waiting Time Secures We Jump Any Line to Enhance Customers’ Travel Experience

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!
  • Trending
  • Comments
  • Latest

Jay Bhattacharya on Public Health

October 12, 2021

Microsoft Planner vs Trello: Which Project Management Tool is Better?

May 24, 2023

That Bangladesh Mask Study!

December 1, 2021

Antitrust Regulation Assumes Bureaucrats Know the “Correct” Amount of Competition

November 24, 2021
UK tech scale-ups lag on gender diversity as over a third have no women on their boards

UK tech scale-ups lag on gender diversity as over a third have no women on their boards

0

0

0

0
UK tech scale-ups lag on gender diversity as over a third have no women on their boards

UK tech scale-ups lag on gender diversity as over a third have no women on their boards

November 6, 2025

John 5’s Story Sparks Interest in Herbal Therapy for Chronic Nonbacterial Prostatitis

November 6, 2025

Financial Times Calls Thinkers50 “The Oscars of Management Thinking”

November 6, 2025

The Duke of Edinburgh Appointed Royal Patron of the Ulysses Trust

November 6, 2025

Recent News

UK tech scale-ups lag on gender diversity as over a third have no women on their boards

UK tech scale-ups lag on gender diversity as over a third have no women on their boards

November 6, 2025

John 5’s Story Sparks Interest in Herbal Therapy for Chronic Nonbacterial Prostatitis

November 6, 2025

Financial Times Calls Thinkers50 “The Oscars of Management Thinking”

November 6, 2025

The Duke of Edinburgh Appointed Royal Patron of the Ulysses Trust

November 6, 2025

Disclaimer: ElonsVision.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

  • Contacts
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 ElonsVision. All Rights Reserved.

No Result
View All Result
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock

Copyright © 2025 ElonsVision. All Rights Reserved.